Magdalena Cerdá1,2, William R Ponicki3, Nathan Smith2, Ariadne Rivera-Aguirre1,2, Corey S Davis4, Brandon D L Marshall5, David S Fink6, Stephen G Henry7, Alvaro Castillo-Carniglia2,8, Garen J Wintemute2, Andrew Gaidus3, Paul J Gruenewald3, Silvia S Martins6. 1. From the Department of Population Health, NYU School of Medicine, New York, NY. 2. Violence Prevention Research Program, Department of Emergency Medicine, UC Davis School of Medicine, CA. 3. Prevention Research Center, Pacific Institute for Research and Evaluation, Berkeley, CA. 4. Network for Public Health Law, Los Angeles, CA. 5. Department of Epidemiology, Brown University School of Public Health, Providence, RI. 6. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY. 7. Department of Internal Medicine, University of California Davis, Sacramento, CA. 8. Society and Health Research Center, Facultad de Humanidades, Universidad Mayor, Chile.
Abstract
BACKGROUND: Prescription drug monitoring programs (PDMPs) that collect and distribute information on dispensed controlled substances have been adopted by nearly all US states. We know little about program characteristics that modify PDMP impact on prescription opioid (PO) overdose deaths. METHODS: We measured associations between adoption of any PDMP and changes in fatal PO overdoses in 2002-2016 across 3109 counties in 49 states and D.C. We then measured changes related to the adoption of "proactive PDMPs," which report outlying prescribing/dispensing patterns and provide broader access to PDMP data by law enforcement. Comparisons were made within 3 time intervals that broadly represent the evolution of PDMPs (2002-2004, 2005-2009, and 2010-2016). We modeled overdoses using Bayesian space-time models. RESULTS: Adoption of electronic PDMP access was associated with 9% lower rates of fatal PO overdoses after three years (rate ratio [RR] = 0.91, 95% credible interval [CI]: 0.88-0.93) with well-supported effects for methadone (RR = 0.86,95% CI: 0.82-0.90) and other synthetic opioids (RR = 0.82, 95% CI: 0.77-0.86). Compared with states with no/weak PDMPs, proactive PDMPs were associated with fewer deaths attributed to natural/semi-synthetic opioids (2002-2004: RR = 0.72 [0.66-0.78]; 2005-2009: RR = 0.93 [0.90-0.97]; 2010-2016: 0.89 [0.86-0.92]) and methadone (2002-2004: RR = 0.77 [0.69-0.85]; 2010-2016: RR = 0.90 [0.86-0.94]). Unintended effects were observed for synthetic opioids other than methadone (2005-2009: RR = 1.29 [1.21-1.38]; 2010-2016: RR = 1.22 [1.16-1.29]). CONCLUSIONS: State adoption of PDMPs was associated with fewer PO deaths overall while proactive PDMPs alone were associated with fewer deaths related to natural/semisynthetic opioids and methadone, the specific targets of these programs. See video abstract at, http://links.lww.com/EDE/B619.
BACKGROUND: Prescription drug monitoring programs (PDMPs) that collect and distribute information on dispensed controlled substances have been adopted by nearly all US states. We know little about program characteristics that modify PDMP impact on prescription opioid (PO) overdose deaths. METHODS: We measured associations between adoption of any PDMP and changes in fatal PO overdoses in 2002-2016 across 3109 counties in 49 states and D.C. We then measured changes related to the adoption of "proactive PDMPs," which report outlying prescribing/dispensing patterns and provide broader access to PDMP data by law enforcement. Comparisons were made within 3 time intervals that broadly represent the evolution of PDMPs (2002-2004, 2005-2009, and 2010-2016). We modeled overdoses using Bayesian space-time models. RESULTS: Adoption of electronic PDMP access was associated with 9% lower rates of fatal PO overdoses after three years (rate ratio [RR] = 0.91, 95% credible interval [CI]: 0.88-0.93) with well-supported effects for methadone (RR = 0.86,95% CI: 0.82-0.90) and other synthetic opioids (RR = 0.82, 95% CI: 0.77-0.86). Compared with states with no/weak PDMPs, proactive PDMPs were associated with fewer deaths attributed to natural/semi-synthetic opioids (2002-2004: RR = 0.72 [0.66-0.78]; 2005-2009: RR = 0.93 [0.90-0.97]; 2010-2016: 0.89 [0.86-0.92]) and methadone (2002-2004: RR = 0.77 [0.69-0.85]; 2010-2016: RR = 0.90 [0.86-0.94]). Unintended effects were observed for synthetic opioids other than methadone (2005-2009: RR = 1.29 [1.21-1.38]; 2010-2016: RR = 1.22 [1.16-1.29]). CONCLUSIONS: State adoption of PDMPs was associated with fewer PO deaths overall while proactive PDMPs alone were associated with fewer deaths related to natural/semisynthetic opioids and methadone, the specific targets of these programs. See video abstract at, http://links.lww.com/EDE/B619.
Authors: Hilary L Surratt; Catherine O'Grady; Steven P Kurtz; Yamilka Stivers; Theodore J Cicero; Richard C Dart; Minxing Chen Journal: Pharmacoepidemiol Drug Saf Date: 2014-03 Impact factor: 2.890
Authors: Chris Delcher; Alexander C Wagenaar; Bruce A Goldberger; Robert L Cook; Mildred M Maldonado-Molina Journal: Drug Alcohol Depend Date: 2015-02-19 Impact factor: 4.492
Authors: Nathan Smith; Silvia S Martins; June Kim; Ariadne Rivera-Aguirre; David S Fink; Alvaro Castillo-Carniglia; Stephen G Henry; Stephen J Mooney; Brandon D L Marshall; Corey Davis; Magdalena Cerdá Journal: Addiction Date: 2018-10-22 Impact factor: 6.526
Authors: Dhruv S Gaur; Brendan P Jacka; Traci C Green; Elizabeth A Samuels; Scott E Hadland; Maxwell S Krieger; Jesse L Yedinak; Brandon D L Marshall Journal: Int J Drug Policy Date: 2020-10-16
Authors: Emma E McGinty; Mark C Bicket; Nicholas J Seewald; Elizabeth A Stuart; G Caleb Alexander; Colleen L Barry; Alexander D McCourt; Lainie Rutkow Journal: Ann Intern Med Date: 2022-03-15 Impact factor: 51.598
Authors: Silvia S Martins; William Ponicki; Nathan Smith; Ariadne Rivera-Aguirre; Corey S Davis; David S Fink; Alvaro Castillo-Carniglia; Stephen G Henry; Brandon D L Marshall; Paul Gruenewald; Magdalena Cerdá Journal: Int J Drug Policy Date: 2019-10-15
Authors: Valerie S Harder; Susan E Varni; Kimberly A Murray; Timothy B Plante; Andrea C Villanti; Daniel L Wolfson; Sanchit Maruti; Kathleen M Fairfield Journal: Int J Drug Policy Date: 2021-06-06
Authors: Magdalena Cerdá; Katherine Wheeler-Martin; Emilie Bruzelius; William Ponicki; Paul Gruenewald; Christine Mauro; Stephen Crystal; Corey S Davis; Katherine Keyes; Deborah Hasin; Kara E Rudolph; Silvia S Martins Journal: Am J Epidemiol Date: 2021-12-01 Impact factor: 5.363